About Us

For 18 years, Bright Pink helped save the lives of countless young women by developing, accelerating, and expanding the impact of life-saving breast and ovarian health interventions.

Bright Pink: Awareness in Action

For 18 years, Bright Pink empowered young women nationwide to know their risk and manage their health proactively, providing actionable information and support online and in healthcare settings, schools, workplaces and communities. Through award-winning digital tools, high-impact programs, and strategic partnerships with world-class brands and organizations, Bright Pink transformed the national conversation about breast and ovarian cancer from one centered around awareness to one focused on life-saving action. Bright Pink guided 1.8 million women to assess their risk and take proactive steps, educated 110,000+ women through in-person workshops and trained 20,000 women's health providers to deliver better care for their high-risk patients.

In 2021, Dana-Farber Cancer Institute acquired Bright Pink's original suite of programs and tools including AssessYourRisk.org, and Bright Pink transitioned to work alongside five Mission Partners through a venture philanthropy model. By investing assets, expertise, and capacity-building support into cutting-edge interventions, Bright Pink helped reduce breast and ovarian health disparities and enable thousands of young women to access life-saving care.

In 2024, Bright Pink made its final legacy gift to establish the Bright Pink Preventive Risk Outreach And Cascade Testing (PROACT) Program at Stanford Medicine. Led by world-renowned leaders Dr. Allison Kurian and Dr. Jennifer Caswell-Jin, the PROACT Program aims to revolutionize cascade testing by making it accessible, immediate and effective, helping Bright Pink fulfill its mission at scale. Cascade testing enables individuals at an increased risk for breast and ovarian cancer to share this information with family members who can use the knowledge to manage their own risk and take life-saving, preventive action. This gift intends to democratize access to one of the most promising medical interventions benefitting young women today and ensure future generations never have to experience the burden of a breast or ovarian cancer diagnosis.

Guiding Values

Over the course of our 18 years of work and in determining our legacy investment, we relied on these values to guide our way.